DE2139610A1 - Verfahren zum Induzieren eines zellular-immunen Ansprechens auf Antigene und Produkte derselben - Google Patents
Verfahren zum Induzieren eines zellular-immunen Ansprechens auf Antigene und Produkte derselbenInfo
- Publication number
- DE2139610A1 DE2139610A1 DE19712139610 DE2139610A DE2139610A1 DE 2139610 A1 DE2139610 A1 DE 2139610A1 DE 19712139610 DE19712139610 DE 19712139610 DE 2139610 A DE2139610 A DE 2139610A DE 2139610 A1 DE2139610 A1 DE 2139610A1
- Authority
- DE
- Germany
- Prior art keywords
- tuberculosis
- digested
- antigen
- recovered
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 title claims description 43
- 102000036639 antigens Human genes 0.000 title claims description 43
- 108091007433 antigens Proteins 0.000 title claims description 43
- 238000000034 method Methods 0.000 title claims description 16
- 230000024932 T cell mediated immunity Effects 0.000 title description 4
- 230000001939 inductive effect Effects 0.000 title description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 14
- 108090000631 Trypsin Proteins 0.000 claims description 13
- 102000004142 Trypsin Human genes 0.000 claims description 13
- 230000003053 immunization Effects 0.000 claims description 13
- 239000012588 trypsin Substances 0.000 claims description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 230000011987 methylation Effects 0.000 claims description 11
- 238000007069 methylation reaction Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 229960001005 tuberculin Drugs 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 238000007710 freezing Methods 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 4
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- 239000002609 medium Substances 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 239000007762 w/o emulsion Substances 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 2
- 229960002109 tuberculosis vaccine Drugs 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 claims 11
- 108090000317 Chymotrypsin Proteins 0.000 claims 2
- 229960002376 chymotrypsin Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108091005804 Peptidases Proteins 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims 1
- 238000001179 sorption measurement Methods 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 20
- 241000304886 Bacilli Species 0.000 description 14
- 238000002255 vaccination Methods 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 8
- 238000005886 esterification reaction Methods 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 238000002649 immunization Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 5
- 230000032050 esterification Effects 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000002569 water oil cream Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000037386 Typhoid Diseases 0.000 description 3
- 241000700647 Variola virus Species 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000005189 flocculation Methods 0.000 description 3
- 230000016615 flocculation Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 201000008297 typhoid fever Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000002365 anti-tubercular Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000036647 reaction Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000035742 Air-borne transmission Diseases 0.000 description 1
- 241000223205 Coccidioides immitis Species 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000005557 airborne transmission Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 201000003486 coccidioidomycosis Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10572771A | 1971-01-11 | 1971-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2139610A1 true DE2139610A1 (de) | 1972-07-27 |
Family
ID=22307466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19712139610 Pending DE2139610A1 (de) | 1971-01-11 | 1971-08-04 | Verfahren zum Induzieren eines zellular-immunen Ansprechens auf Antigene und Produkte derselben |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE2139610A1 (enExample) |
| FR (1) | FR2121499B1 (enExample) |
| GB (1) | GB1301795A (enExample) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE417443C (de) * | 1923-06-09 | 1925-08-12 | Hoechst Ag | Verfahren zur Darstellung von wasser-, alkohol- und oelloeslichen Tuberkulinpraeparaten |
-
1971
- 1971-08-04 DE DE19712139610 patent/DE2139610A1/de active Pending
- 1971-09-17 GB GB4358771A patent/GB1301795A/en not_active Expired
- 1971-10-12 FR FR7137754A patent/FR2121499B1/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR2121499A1 (enExample) | 1972-08-25 |
| GB1301795A (enExample) | 1973-01-04 |
| FR2121499B1 (enExample) | 1975-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69615362T3 (de) | Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein | |
| DE69319728T2 (de) | Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten | |
| DE60210456T2 (de) | Solubilisierung von capsulären Polysacchariden | |
| DE3712767C2 (enExample) | ||
| DE3806565C2 (enExample) | ||
| DE2547105A1 (de) | N-acetyl-muramyl-l-alanyl-d-isoglutamin enthaltende oelfreie adjuvanzien | |
| DE3024282A1 (de) | Vakzinierende glycopeptid-antigenfraktion mit grosser immunisierungsfaehigkeit, isoliert aus kulturen pathogener keime, verfahren zur isolierung dieser fraktion und diese enthaltende vakzinen | |
| DE3787887T2 (de) | Verfahren zum Züchten von Bordetella-Pertussis, ein Pertussis-Toxoid und ein Pertussis-Impfstoff. | |
| DE2355094A1 (de) | Tetanus-vaccine und verfahren zu deren herstellung | |
| DE68914362T2 (de) | Impfstoff, geeignet zur Verhütung bzw. Kontrolle der durch Haemophilus pleuropneumoniae verursachte Schweinekrankheit und Verfahren zu dessen Herstellung. | |
| DE2262427C3 (de) | Immunostimulierendes Mittel | |
| DE2010788A1 (de) | Wasserunlösliche Substanzen mit Antigenwirkung und Verfahren zu ihrer Herstellung | |
| EP0445710A1 (de) | Verwendung von Zink-Calciumhydroxid, Lecithin und PAO zur Adjuvierung von Antigenlösungen und auf diese Weise adjuvierte Antigenlösungen | |
| DE2139610A1 (de) | Verfahren zum Induzieren eines zellular-immunen Ansprechens auf Antigene und Produkte derselben | |
| DE1617545A1 (de) | Antigenfreie Vaccine | |
| DE2845745C2 (enExample) | ||
| DE69333402T2 (de) | Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1 | |
| US2385443A (en) | Process of preparing concentrated toxoids and product produced thereby | |
| DE191752C (enExample) | ||
| DE2121237C3 (de) | Verwendung einer Zellinie zur Züchtung von Viren | |
| DE2756851A1 (de) | Adjuvantien unspezifischer immunitaet | |
| DE69907921T2 (de) | Salmonella typhi impfstoffzusammensetzungen | |
| CH652028A5 (de) | Extrakt aus pflanzen vom genus epimedium sp., verfahren zur herstellung dieses extrakts und verwendung des extrakts als wirksame komponente in einem immunstimulierenden mittel. | |
| DE1902590C2 (de) | Verwendung einer Immunribonucleinsäure (IRNS) zum Immunisieren lebender Tiere | |
| DE2713680A1 (de) | Verfahren zur herstellung eines mittels mit mitogenen und/oder adjuvans-eigenschaften und dieses mittel enthaltende arzneimittel |